BAXTER INTERNATIONAL INC acquires Transderm Scop (TDS) rights (from subsidiaries of GlaxoSmithKline)
Snapshot
BAXTER INTERNATIONAL INC acquired Transderm Scop (TDS) rights (from subsidiaries of GlaxoSmithKline) for $60 million upfront purchase price (including acquired inventory) plus up to $30 million additional contingent consideration (acquisition-date fair value $24 million) in March 2021. The transaction was structured as all cash (with contingent consideration). Transderm Scop (TDS) rights (from subsidiaries of GlaxoSmithKline) is a Rights for the U.S. and specified ex-US territories (acquired from GlaxoSmithKline subsidiaries)-based Pharmaceuticals business.
- Acquirer
- BAXTER INTERNATIONAL INC
- Target
- Transderm Scop (TDS) rights (from subsidiaries of GlaxoSmithKline)
- Value
- $60 million upfront purchase price (including acquired inventory) plus up to $30 million additional contingent consideration (acquisition-date fair value $24 million)
- Date
- March 2021
- Type
- asset purchase
- Status
- ready
The deal at a glance
About this deal
BAXTER INTERNATIONAL INC acquired Transderm Scop (TDS) rights (from subsidiaries of GlaxoSmithKline) for $60 million upfront purchase price (including acquired inventory) plus up to $30 million additional contingent consideration (acquisition-date fair value $24 million), a transaction completed in March 2021, structured as all cash (with contingent consideration). The deal was a asset purchase.
Transderm Scop (TDS) rights (from subsidiaries of GlaxoSmithKline) operates in Pharmaceuticals, is based in Rights for the U.S. and specified ex-US territories (acquired from GlaxoSmithKline subsidiaries). Transderm Scop (TDS) is a transdermal patch used to prevent nausea and vomiting in the U.S. and motion sickness in European markets; Baxter acquired the rights for the U.S. and specified territories outside the U.S. from subsidiaries of GlaxoSmithKline.
Expands Baxter's pharmaceuticals portfolio with an established branded transdermal product.
Established branded transdermal product expanding Baxter's pharmaceuticals portfolio. Integrated into Baxter's pharmaceuticals business
No advisory firms have been disclosed for this transaction.